Portal de Periódicos da CAPES

Cell Surface A, B or O(H) Blood Group Antigens as an Indicator of Malignant Potential in Stage A Bladder Carcinoma

1980; Lippincott Williams & Wilkins; Volume: 124; Issue: 1 Linguagem: Inglês

10.1016/s0022-5347(17)55275-1

1527-3792

Alfred Newman, C. Eugene Carlton, Sarah Johnson,

Urologic and reproductive health conditions

No AccessJournal of Urology1 Jul 1980Cell Surface A, B or O(H) Blood Group Antigens as an Indicator of Malignant Potential in Stage A Bladder Carcinoma Alfred J. Newman, C. Eugene Carlton, and Sarah Johnson Alfred J. NewmanAlfred J. Newman More articles by this author , C. Eugene CarltonC. Eugene Carlton More articles by this author , and Sarah JohnsonSarah Johnson More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)55275-1AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The major blood group antigens A, B or O(H) are present on normal bladder epithelium. The presence or absence of these antigens on the cell surface of bladder tumors has been determined in a retrospective longitudinal study using biopsy material from 322 patients who fit the following criteria: 1) the patient presented initially with a superficial bladder tumor, 2) the patient had followup examination for at least 5 years or until evidence of tumor invasion of bladder muscle and 3) the paraffin-embedded tumor specimens were still available. Of 80 patients with stage A tumors that subsequently became invasive 71 (88 per cent) showed deletion of A, B or H antigens from the original superficial tumor. On the other hand, of 146 patients who had no recurrence of superficial tumor for at least 5 years 127 (87 per cent) retained A, B or H antigens. Of 96 patients who had 1 or more superficial recurrences 87 (90 per cent) retained antigens on the initial and subsequent tumors. Analysis of transitional cell surface antigens should help in the Identification of those patients with superficial disease who are at greatest risk for invasive bladder cancer. © 1980 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byKlatte T, Xylinas E, Rieken M, Kluth L, Rouprêt M, Pycha A, Fajkovic H, Seitz C, Karakiewicz P, Lotan Y, Babjuk M, de Martino M, Scherr D and Shariat S (2013) Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 191, NO. 5, (1238-1243), Online publication date: 1-May-2014.STEIN J, GROSSFELD G, GINSBERG D, ESRIG D, FREEMAN J, FIGUEROA A, SKINNER D and COTE R (2018) PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATUREJournal of Urology, VOL. 160, NO. 3 Part 1, (645-659), Online publication date: 1-Sep-1998.Okamura K, Miyake K, Koshikawa T and Asai J (2018) Growth Fractions of Transitional Cell Carcinomas of the Bladder Defined by the Monoclonal Antibody KI-67Journal of Urology, VOL. 144, NO. 4, (875-878), Online publication date: 1-Oct-1990.Takahashi N, Takahashi S, Takahashi K, Suzuki T and Funyu T (2018) A Monoclonal Antibody to Human Transitional Cell Carcinoma of the Bladder: Production and CharacterizationJournal of Urology, VOL. 138, NO. 1, (207-211), Online publication date: 1-Jul-1987.Arndt R, Dürkopf H, Huland H, Donn F, Loening T and Kalthoff H (2018) Monoclonal Antibodies for Characterization of the Heterogeneity of Normal and Malignant Transitional CellsJournal of Urology, VOL. 137, NO. 4, (758-763), Online publication date: 1-Apr-1987.Takai K, Kakizoe T, Serine T, Sato S and Njima T (2018) Analyses of Avidin-biotin Complexes With Lectins of Membrane Glycoproteins in the Urinary Bladder of Rats Treated With N-butyl-N-(4-hydroxybutyl)nitrosamineJournal of Urology, VOL. 137, NO. 1, (136-139), Online publication date: 1-Jan-1987.Murphy W, Blatnik A, Shelton T and Soloway M (2018) Carcinogenesis in Mammalian Urothelium: Changes Induced by Non-Carcinogenic Substances and Chronic Indwelling CathetersJournal of Urology, VOL. 135, NO. 4, (840-844), Online publication date: 1-Apr-1986.Cuadrado E, Rodriguez-Trinidad A, Blasco E, Torrado J, Lopez Garcia J and Arozena F (2018) Blood Group Isoantigens ABO (H) in Transitional Carcinoma of the Bladder: A Clinicopathological StudyJournal of Urology, VOL. 135, NO. 2, (409-415), Online publication date: 1-Feb-1986.Borgström E and Wahren B (2018) Quantitative Analysis of the A, B and H Isoantigens in Single Transitional Carcinoma CellsJournal of Urology, VOL. 134, NO. 1, (199-202), Online publication date: 1-Jul-1985.Seal G, Rowland R, Thomalla J, Rudolph R, Pfaff D, Kamer M and Eble J (2018) A, B and H Antigens in Normal Urothelium: An Immunohistochemical Study Using Monoclonal Antibodies with the Avidin-Biotin Complex TechniqueJournal of Urology, VOL. 133, NO. 3, (513-516), Online publication date: 1-Mar-1985.Srinivas V, Orihuela E, Lloyd K, Old L and Whitmore W (2018) Estimation of ABO(H) Isoantigen Expression in Bladder TuiviorsJournal of Urology, VOL. 133, NO. 1, (25-28), Online publication date: 1-Jan-1985.Srinivas V and Kiruluta H (2018) ABO(H) Isoantigens in Bladder Tumors: A New Technique of Quantitative AnalysisJournal of Urology, VOL. 131, NO. 2, (245-248), Online publication date: 1-Feb-1984.Akaza H, Murphy W and Soloway M (2018) Bladder Cancer Induced by Noncarcinogenic SubstancesJournal of Urology, VOL. 131, NO. 1, (152-155), Online publication date: 1-Jan-1984.Catalona W (2018) Editorial CommentJournal of Urology, VOL. 130, NO. 5, (873-873), Online publication date: 1-Nov-1983.King C, Clark T, Lovett J, Cash J, Primus F, McRoberts J and Flanigan R (2018) A Comparison of Clinical Course with Blood Group Antigen Testing by Specific Red Cell Adherence and Immunoperoxidase in Ureteral and Renal Pelvic TumorsJournal of Urology, VOL. 130, NO. 5, (871-873), Online publication date: 1-Nov-1983.Catalona W (2018) Editorial CommentJournal of Urology, VOL. 128, NO. 6, (1189-1189), Online publication date: 1-Dec-1982.Ghazizadeh M, Kagawa S and Kurokawa K (2018) Specific Red Cell Adherence Testing of Benign and Malignant Lesions of the UrethraJournal of Urology, VOL. 128, NO. 6, (1188-1189), Online publication date: 1-Dec-1982.Sarosdy M and Lamm D (2018) Application of the Mixed Cell Agglutination Test for Cell Surface Antigens to Renal Cell CarcinomaJournal of Urology, VOL. 128, NO. 4, (693-696), Online publication date: 1-Oct-1982.Wiley E, Mendelsohn G, Droller M and Eggleston J (2018) Immunoperoxidase Detection of Carcinoembryonic Antigen and Blood Group Substances in Papillary Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 128, NO. 2, (276-280), Online publication date: 1-Aug-1982.Droller M (2018) Editorial CommentJournal of Urology, VOL. 127, NO. 4, (666-667), Online publication date: 1-Apr-1982.D’Elia F, Cooper H and Grant Mulholland S (2018) ABH Isoantigens in Stage O Papillary Transitional Cell Carcinoma of the Bladder: Correlation with Biological BehaviorJournal of Urology, VOL. 127, NO. 4, (665-666), Online publication date: 1-Apr-1982.Emmott R, Droller M and Javadpour N (2018) Studies of A, B or O (H) Surface Antigen Specificity: Carcinoma in Situ and Non-Malignant Lesions of the BladderJournal of Urology, VOL. 125, NO. 1, (32-35), Online publication date: 1-Jan-1981.Lange P and Limas C (2018) Tissue Blood Group Antigen Testing in Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 124, NO. 2, (304-304), Online publication date: 1-Aug-1980. Volume 124Issue 1July 1980Page: 27-29 Advertisement Copyright & Permissions© 1980 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Alfred J. Newman More articles by this author C. Eugene Carlton More articles by this author Sarah Johnson More articles by this author Expand All Advertisement PDF downloadLoading ...